MARC Record from harvard_bibliographic_metadata

LEADER: 03756nam a2200517 a 4500
001 009494835-6
005 20090113200723.0
008 040701s2004 enka b 001 0 eng
010 $a 2004048819
020 $a0470869984 (alk. paper)
035 0 $aocm55877555
040 $aDLC$cDLC$dYDX$dWJ7
042 $apcc
050 00 $aQP552.S65$bB566 2004
060 00 $aW1$bNO9285 v.262 2004
060 10 $aQU 107$bS989b 2004
082 00 $a612/.015756$222
245 00 $aBiology of IGF-1 :$bits interaction with insulin in health and malignant states /$c[edited by Gregory Bock, Jamie Goode].
260 $aChichester, U.K. ;$aHoboken, N.J. :$bJohn Wiley & Sons,$c2004.
300 $aviii, 280 p. :$bill. ;$c24 cm.
440 0 $aNovartis Foundation symposium ;$v262
500 $a"Symposium on Biology of IGF-1: its interaction with insulin in health and melignant states, held at the Novartis Foundation, London, 14-16 October 2003"--Contents p.
504 $aIncludes bibliographical references and indexes.
505 0 $aCirculating IGF-I and its role in cancer: lessons from the IGF-1 gene-deletion (LID) mouse -- Physiology of the IGF system -- Molecular basis of insulin action -- IGF-1 and insulin as growth hormones -- Insulin-like growth factors and neoplasia -- Loss of IGF2 imprinting: mechanisms and consequences -- Insulin and IGF-1 receptor trafficking and signalling -- The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb -- Structural biology of insulin and IGF-1 receptors -- Genetic blockade of the insulin-like growth factor-I receptor for human malignancy -- IGF-1 and prostate cancer.
505 8 $aIGF-1 and breast cancer -- IGFBPs and cancer -- The IGF receptor as anticancer treatment target -- Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence.
530 $aAlso available in an electronic version.
538 $aMode of access: World Wide Web.
520 $aThe clinical use of long-term growth hormone treatment is increasing and such treatment leads to raised IGF-1 levels. Increased insulin levels are also more common as the prevalence of insulin resistance, which frequently presages obesity and/or type 2 diabetes, increases in the population. Therefore, a careful discussion of the role of IGF-1 and insulin in various cancers is urgently needed. This book examines these issues in detail. It features contributions from the leading scientists and clinicians in the field and should prove essential reading for anyone with a clinical interest in insulin and the IGFs.
650 0 $aCarcinogenesis$vCongresses.
650 0 $aSomatomedin$xPathophysiology$vCongresses.
650 0 $aSomatomedin$xPhysiological effect$vCongresses.
650 12 $aInsulin-Like Growth Factor I$xphysiology
650 22 $aCarcinogenicity Tests
655 0 $aElectronic books.
655 2 $aCongresses
655 7 $aComputer network resources.$2local
650 12 $aSomatomedins$xphysiology$vCongresses.
650 22 $aCarcinogenicity Tests$vCongresses.
650 22 $aRisk Assessment$vCongresses.
700 1 $aBock, Gregory.
700 1 $aGoode, Jamie.
740 0 $aBiology of IGF-1 : its interaction with insulin in health and malignant states (Online)$5med
776 08 $iOnline version:$aSymposium on Biology of IGF-1 (2003 : Novartis Foundation)$tBiology of IGF-1.$dThe Atrium, Southern Gate, Chichester, UK ; Hoboken, NJ : John Wiley & Sons, c2004$w(OCoLC)607514059
776 08 $iOnline version:$aSymposium on Biology of IGF-1 (2003 : Novartis Foundation)$tBiology of IGF-1.$dThe Atrium, Southern Gate, Chichester, UK ; Hoboken, NJ : John Wiley & Sons, c2004$w(OCoLC)609346133
988 $a20110721
906 $0DLC